•
Dec 31, 2024

NeueHealth Q4 2024 Earnings Report

NeueHealth reported its Q4 2024 results, returning to profitability with net income of $2.52 million and delivering positive adjusted EBITDA.

Key Takeaways

NeueHealth achieved strong fourth-quarter results, with $232.64 million in revenue and net income of $2.52 million. The company reported positive adjusted EBITDA for the fourth consecutive quarter, highlighting the success of its value-driven, consumer-centric care model.

Q4 2024 revenue was $232,638,000, showing a decrease from the prior year but supported by diversified segments.

Net income for the quarter reached $2,523,000, reversing a significant loss in Q4 2023.

Adjusted EBITDA came in at $5,482,000, compared to negative $10,356,000 in Q4 2023.

The company served 360,000 value-based consumers and 123,000 enablement services lives as of December 31, 2024.

Total Revenue
$233M
Previous year: $293M
-20.6%
EPS
-$1.94
Previous year: $19.5
-109.9%
Medical Cost Ratio
79.5%
Operating Cost Ratio
31.3%
Cash and Equivalents
$83.3M
Previous year: $87.3M
-4.6%
Total Assets
$544M
Previous year: $1.23B
-55.6%

NeueHealth

NeueHealth

NeueHealth Revenue by Segment

Forward Guidance

NeueHealth did not provide explicit financial guidance but emphasized strategic growth in 2025, focusing on expanding consumer reach and payor-provider relationships.

Positive Outlook

  • Continued focus on expanding consumer base in new and existing markets.
  • Building on strong relationships with payors and providers.
  • Sustained positive adjusted EBITDA for four consecutive quarters.
  • Solid foundation for continued financial performance in 2025.
  • Focus on delivering a seamless, coordinated care experience.

Challenges Ahead

  • Revenue decline in Q4 compared to the prior year.
  • Operating loss of $29.4 million in Q4 2024.
  • High medical and operating costs impacting profitability.
  • Potential headwinds from industry and regulatory changes.
  • Uncertainty regarding the upcoming merger and future operational structure.